Identification and Characterization of ML352: A Novel, Noncompetitive Inhibitor of the Presynaptic Choline Transporter-Reference-Cited by-同舟云学术

Identification and Characterization of ML352: A Novel, Noncompetitive Inhibitor of the Presynaptic Choline Transporter

Published:2015-02-02 Issue:3 Volume:6 Page:417-427
ISSN:1948-7193
Container-title:ACS Chemical Neuroscience
language:en
Short-container-title:ACS Chem. Neurosci.

Author:

Ennis Elizabeth A.,Wright Jane,Retzlaff Cassandra L.,McManus Owen B.¹,Lin Zhinong¹,Huang Xiaofang¹,Wu Meng¹,Li Min¹,Daniels J. Scott,Lindsley Craig W.,Hopkins Corey R.,Blakely Randy D.

Affiliation:

1. Johns Hopkins University Ion Channel Center, Baltimore, Maryland 21205, United States

Funder

National Center for Advancing Translational Sciences

Alzheimer's Association

National Institute of Mental Health

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Cell Biology,Cognitive Neuroscience,Physiology,Biochemistry,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/cn5001809

Reference68 articles.

1. Cholinergic modulation of mesolimbic dopamine function and reward

2. Modes and Models of Forebrain Cholinergic Neuromodulation of Cognition

3. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functional and Biochemical Consequences of Disease Variants in Neurotransmitter Transporters: A Special Emphasis on Folding and Trafficking Deficits;Pharmacology & Therapeutics;2021-06

2. Competitive inhibition of the high-affinity choline transporter by tetrahydropyrimidine anthelmintics;European Journal of Pharmacology;2021-05

3. Modulation of sodium-coupled choline transporter CHT function in health and disease;Neurochemistry International;2020-11

4. ChoK-ing the Pathogenic Bacteria: Potential of Human Choline Kinase Inhibitors as Antimicrobial Agents;BioMed Research International;2020-07-10

5. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease;Expert Opinion on Drug Metabolism & Toxicology;2020-06-23